Onconova Therapeutics (ONTX) Getting Positive Media Coverage, Report Finds

News headlines about Onconova Therapeutics (NASDAQ:ONTX) have been trending positive recently, Accern Sentiment reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Onconova Therapeutics earned a coverage optimism score of 0.25 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.7670829123426 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern’s rankings:

Onconova Therapeutics (ONTX) opened at $1.51 on Wednesday. Onconova Therapeutics has a 1 year low of $1.46 and a 1 year high of $3.88.

Onconova Therapeutics (NASDAQ:ONTX) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.29 million. Onconova Therapeutics had a negative return on equity of 558.97% and a negative net margin of 2,855.94%. research analysts forecast that Onconova Therapeutics will post -2.82 EPS for the current year.

A number of brokerages have weighed in on ONTX. HC Wainwright restated a “buy” rating on shares of Onconova Therapeutics in a research note on Thursday, November 9th. Maxim Group set a $6.00 target price on Onconova Therapeutics and gave the stock a “buy” rating in a research note on Thursday, November 9th. Finally, ValuEngine upgraded Onconova Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $7.33.

TRADEMARK VIOLATION NOTICE: “Onconova Therapeutics (ONTX) Getting Positive Media Coverage, Report Finds” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.com-unik.info/2017/12/06/onconova-therapeutics-ontx-getting-positive-media-coverage-report-finds.html.

Onconova Therapeutics Company Profile

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells.

Insider Buying and Selling by Quarter for Onconova Therapeutics (NASDAQ:ONTX)

What are top analysts saying about Onconova Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Onconova Therapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit